Other companies concentrated their research activities on discovering FXa inhibitors (Pinto et al., 2010) including two recently approved FXa inhibitors – rivaroxaban and apixaban for treatment and prevention of VTE after orthopedic surgery (Pinto et al., 2007; Perzborn et al., 2011) and stroke prevention in atrial fibrillation (Granger et al., 2011; Patel et al., 2011). The gene discussed is F10; the disease is atrial fibrillation.